Target intelligence / Profile preview

ATP synthase peripheral stalk subunit F6 (F6)

Target
F6
Molecular classification
Enzyme (as a subunit of ATP synthase, which is an enzyme complex), Mitochondrial protein, Peripheral stalk component (stator)
01

Overview

ATP synthase peripheral stalk subunit F6 is a nuclear-encoded protein component of the mammalian mitochondrial ATP synthase complex (complex V). It forms a critical part of the peripheral stalk (stator), which anchors the enzyme’s catalytic head (F1 sector) to the membrane sector (FO) and prevents its rotation as protons drive rotary catalysis for synthesis of ATP from ADP and inorganic phosphate[1][2]. F6 interacts with other stator proteins such as subunit b, OSCP, and subunit d. Mutation or loss of F6 disrupts complex assembly and coupling between proton movement and ATP production, severely impairing mitochondrial function[2]. Although ATP synthase is a validated therapeutic target in some contexts (especially in infectious disease and cancer research), direct small-molecule targeting of the F6 subunit has not been reported, and inhibitors act broader on the complex. F6 is encoded in humans by the ATP5J gene and is analogous to subunit h in yeast[2].

Other names
Subunit F6ATP synthase subunit F6ATP5J (gene symbol)Peripheral stalk subunit F6Subunit h (yeast ortholog)
02

Mechanism of action

Inhibition of ATP synthase (prevents ATP production by disrupting proton channel or complex stability)

03

Biological functions

Cellular energy metabolism (ATP production by oxidative phosphorylation)Structural stabilization of ATP synthase (forms the peripheral stalk/stator, holding the complex’s catalytic head stationary during rotary catalysis)Coupling proton movement to ATP synthesis
04

Disease associations

Mitochondrial disease (dysfunction can impact energy metabolism)Other (potential, as mutations in ATP synthase subunits are implicated in neuromuscular and metabolic disorders, though direct clinical data on F6-specific variants is limited)
05

Safety considerations

ATP synthase inhibition causes severe energy depletion (potential toxicity to all metabolically active tissues)Mitochondrial dysfunction, lactic acidosis, neuromuscular toxicity, organ failure (potential outcomes of targeting ATP synthase)
06

Interacting drugs

Oligomycin (an ATP synthase inhibitor—acts at the enzyme level, not directly proven at F6 subunit but affects the entire complex)

2 more in the full profile.

07

Biomarkers

Null (no current evidence F6 is used alone as a clinical biomarker for patient selection or monitoring)

Beyond the preview

Go deeper on ATP synthase peripheral stalk subunit F6 (F6).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ATP synthase peripheral stalk subunit F6 (F6).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call